GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of BMY
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Bristol-Myers Squibb stock price up 1.30% on Friday
(Updated on Apr 19, 2024)

Hold candidate since Apr 18, 2024 Gain 1.30% PDF

The Bristol-Myers Squibb stock price gained 1.30% on the last trading day (Friday, 19th Apr 2024), rising from $48.30 to $48.93. During the last trading day the stock fluctuated 1.93% from a day low at $48.12 to a day high of $49.05. The price has fallen in 6 of the last 10 days and is down by -4.66% for this period. Volume fell on the last day by -2 million shares and in total, 8 million shares were bought and sold for approximately $395.69 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the lower part of a wide and weak rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $47.89 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 3.06% during the next 3 months and, with a 90% probability hold a price between $49.36 and $56.80 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

BMY Signals & Forecast

There are mixed signals in the stock today. The Bristol-Myers Squibb stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $51.55. On a fall, the stock will find some support from the short-term average at $48.46. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). A buy signal was issued from a pivot bottom point on Wednesday, April 17, 2024, and so far it has risen 2.28%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss for Bristol-Myers Squibb stock

Bristol-Myers Squibb finds support from accumulated volume at $48.71 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.93 between high and low, or 1.93%. For the last week, the stock has had daily average volatility of 1.63%.

Bristol-Myers Squibb is oversold on RSI14 (24). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: $46.39 (-5.20%) (This stock has medium daily movements and this gives medium risk. Low RSI14 is 24 which reduces the risk some. There is a buy signal from a pivot bottom found 2 days ago.)

Trading Expectations (BMY) For The Upcoming Trading Day Of Monday 22nd

For the upcoming trading day on Monday, 22nd we expect Bristol-Myers Squibb Company to open at $48.70, and during the day (based on 14 day Average True Range), to move between $48.01 and $49.85, which gives a possible trading interval of +/-$0.92 (+/-1.89%) up or down from last closing price. If Bristol-Myers Squibb Company takes out the full calculated possible swing range there will be an estimated 3.77% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $48.71 (0.45%) than the resistance at $49.86 (1.90%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Earnings coming up

Bristol-Myers Squibb will release earnings BMO on Thursday, April 25, 2024.The consensus among the analysts for the expected earnings (EPS) is -$4.51. We will update the financials statements for Bristol-Myers Squibb, that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 3.91% in the first trading day after earnings release.

Is Bristol-Myers Squibb Company stock A Buy?

Bristol-Myers Squibb holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Current score: -0.021 Hold/Accumulate Unchanged

Predicted Opening Price for Bristol-Myers Squibb Company of Monday, April 22, 2024

Fair opening price April 22, 2024 Current price
$48.70 ( 0.472%) $48.93

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for BMY

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 49.63 1.42 %
R2 49.27 0.700 %
R1 49.05 0.252 %
Current price: 48.93
Support S1 48.34 -1.20 %
S2 48.13 -1.64 %
S3 47.77 -2.37 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 51.59 5.44 %
R2 50.92 4.07 %
R1 49.86 1.90 %
Current price 48.93
Support S1 48.71 -0.450%
S2 48.67 -0.531%
S3 47.98 -1.94%

BMY Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 May 06, 2024 May 06, 2024 Jun 03, 2024 $0.500 1.02%
2 Mar 01, 2024 Apr 04, 2024 May 01, 2024 $0.600 1.23%
3 Dec 06, 2023 Jan 04, 2024 Feb 01, 2024 $0.600 1.23%
4 Sep 20, 2023 Oct 05, 2023 Nov 01, 2023 $0.570 1.11%
5 Jun 14, 2023 Jul 06, 2023 Aug 01, 2023 $0.570 0.93%

FAQ

What is the symbol for Bristol-Myers Squibb Stock and on which exchange is it traded?
The symbol for Bristol-Myers Squibb is BMY and it is traded on the NYSE (New York Stock Exchange).

Should I buy or sell Bristol-Myers Squibb Stock?
Bristol-Myers Squibb holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Bristol-Myers Squibb Stock?
Bristol-Myers Squibb Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Bristol-Myers Squibb Stock.

What's the current price of Bristol-Myers Squibb Stock?
As of the end of day on the 2024-04-19, the price of an Bristol-Myers Squibb (BMY) share was $48.93.

What is the 52-week high and low for Bristol-Myers Squibb Stock?
The 52-week high for Bristol-Myers Squibb Stock is $70.94 and the 52-week low is $47.58.

What is the market capitalization of Bristol-Myers Squibb Stock?
As of the 2024-04-19, the market capitalization of Bristol-Myers Squibb is 99.169B.

When is the next earnings date for Bristol-Myers Squibb?
The upcoming earnings date for Bristol-Myers Squibb is Apr 25, 2024.
Click to get the best stock tips daily for free!

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for th... BMY Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT